サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541461

病院感染治療薬市場レポート：薬剤タイプ、適応症、地域別、2024～2032年

Hospital Infection Therapeutics Market Report by Drug Type, Indication, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 140 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
病院感染治療薬市場レポート：薬剤タイプ、適応症、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の病院感染治療薬市場規模は2023年に125億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに189億米ドルに達し、2024～2032年の間に4.55%の成長率（CAGR）を示すと予測しています。多剤耐性感染症の増加、抗菌薬スチュワードシップの重視、研究開発（R&D）の継続的な進展、世界の医療支出の増加とインフラ整備は、市場成長に影響を与える主要要因の一部です。

病院感染治療薬市場分析

市場の成長と規模世界の病院感染治療薬市場は、院内感染の増加と効果的な治療ソリューションへの需要に牽引され、力強い成長を遂げています。市場規模は、世界の医療支出の増加とインフラ整備に後押しされ、着実に拡大しています。

主要市場促進要因：主要促進要因としては、多剤耐性感染症の蔓延、抗菌薬スチュワードシップ・プログラムに対する意識の高まり、研究開発の継続的な進歩、世界の医療支出の増加などが挙げられます。

技術の進歩：特にゲノミクス、微生物学、免疫学における継続的な技術進歩は、新規創薬対象の発見や、モノクローナル抗体や併用療法などの先進的な病院感染症治療の開発に貢献しています。

産業への応用：病院感染症治療は、血流感染症、尿路感染症（UTI）、手術部位感染症、肺炎など、さまざまな適応症に適用され、それぞれのカテゴリーに関連する特定の課題に対処します。

主要市場動向：抗菌薬スチュワードシップへの注目の高まり、共同研究の増加、製品ポートフォリオ拡充のためのM&A、従来のカテゴリーを超えた代替治療の開発などは、市場の成長を強化する新興動向の一部です。

地理的動向：地域別動向：北米と欧州は、強固な医療インフラと厳格な規制枠組みが需要を牽引しています。一方、アジア太平洋は、医療への投資とインフラ整備の増加により著しい成長を遂げています。

競合情勢：競合情勢は熾烈で、製薬会社は研究開発、戦略的提携、M&Aに取り組んでいます。抗菌薬スチュワードシップの原則に沿った製品開発が重視され、業界戦略を形成しています。

課題と機会：薬剤耐性株の出現は市場開拓の課題となっているが、一方で、病院感染症領域における特定の適応症への対応や、治療法開発のための技術革新の活用には機会があります。

病院感染治療薬市場動向

院内感染（HAI）の増加

病院感染治療薬市場の主要促進要因の一つは、HAIの発生率の上昇です。これらの感染症は、細菌性、ウイルス性、真菌性のものがあり、侵襲的な医療処置、手術、医療機器の使用に関連することが多いです。HAIの蔓延は世界的に大きな問題となっており、これらの感染症を管理・治療するための効果的な治療に対する需要の高まりにつながっています。これに加えて、医療環境内での薬剤耐性病原体の蔓延が、高度で的を絞った治療オプションの必要性をさらに高めており、これらの感染症と効果的に闘うための革新的で強力な治療の開発が必要とされています。

抗菌薬管理プログラムに対する意識の高まり

抗菌薬スチュワードシッププログラムは、抗菌薬耐性の出現と蔓延に対抗するための重要な戦略として注目を集めています。これらのプログラムは、耐性菌の発生を最小限に抑えつつ、患者の転帰を改善するために抗菌薬の使用を最適化することに重点を置いています。抗菌薬スチュワードシップに対する意識の高まりは、薬剤耐性病原体によってもたらされる特定の課題に対処できる新規治療の開発と採用に重点を置くようになり、市場拡大の明るい展望を生み出しています。さらに、世界中の様々な医療機関や規制機関が、抗生物質やその他の抗菌剤の適切な使用を確保するため、抗菌薬スチュワードシップを積極的に推進しており、市場拡大に弾みをつけています。

研究開発活動の著しい進歩

感染症セグメントにおける継続的な研究開発活動は、病院感染治療薬市場の拡大に大きく寄与しています。これに伴い、ゲノム学、微生物学、免疫学の進歩により、感染症のメカニズムに関する貴重な知見が得られ、新規の創薬対象が特定されています。新たな抗菌化合物の発見と併用療法の開拓が市場拡大に寄与しています。これに加え、製薬企業、学術機関、研究機関の広範な協力関係が、モノクローナル抗体、ワクチン、新規抗生物質などの革新的な治療法の発見と開発を後押しし、市場の成長を後押ししています。

医療支出の増加とインフラ整備

世界の医療支出の増加と医療セグメントにおける継続的なインフラ整備が、病院感染治療薬市場の成長を促進しています。これと同時に、多くの政府や民間投資家が病院やクリニックなどの医療施設の拡大や近代化に投資しています。このため、HAIの発生を管理・抑制するための効果的なツールを医療提供者に提供する感染症治療の需要が高まり、市場の成長が加速しています。さらに、新興国における医療インフラの拡大が、病院感染治療薬の新たな市場を開拓しています。医療へのアクセスが向上するにつれて、感染症に関連する医療の課題に対処するための高度な治療オプションに対する需要が急増しています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の病院感染治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • 抗菌薬
  • 抗真菌薬
  • 抗ウイルス薬
  • その他

第7章 市場内訳：適応症別

  • 血流感染症
  • 尿路感染症
  • 手術部位感染
  • 肺炎
  • その他

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Allergan Plc（AbbVie Inc.）
    • AstraZeneca Plc
    • Bayer Aktiengesellschaft
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG（Roche Holding AG）
    • Gilead Sciences Inc.
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi S.A.
図表

List of Figures

  • Figure 1: Global: Hospital Infection Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Infection Therapeutics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hospital Infection Therapeutics Market: Breakup by Drug Type (in %), 2023
  • Figure 4: Global: Hospital Infection Therapeutics Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Hospital Infection Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 6: Global: Hospital Infection Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hospital Infection Therapeutics (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hospital Infection Therapeutics (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Hospital Infection Therapeutics (Pneumonia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Hospital Infection Therapeutics (Pneumonia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Hospital Infection Therapeutics (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Hospital Infection Therapeutics (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: North America: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: North America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: United States: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: United States: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Canada: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Canada: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Asia Pacific: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Asia Pacific: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: China: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: China: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Japan: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Japan: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: India: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: India: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: South Korea: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: South Korea: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Australia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Australia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Indonesia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Indonesia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Europe: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Europe: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Germany: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Germany: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: France: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: France: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: United Kingdom: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: United Kingdom: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Italy: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Italy: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Spain: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Spain: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Russia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Russia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Latin America: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Latin America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Brazil: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Brazil: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Mexico: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Mexico: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Middle East and Africa: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Middle East and Africa: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Global: Hospital Infection Therapeutics Industry: SWOT Analysis
  • Figure 74: Global: Hospital Infection Therapeutics Industry: Value Chain Analysis
  • Figure 75: Global: Hospital Infection Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hospital Infection Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 4: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Hospital Infection Therapeutics Market Structure
  • Table 6: Global: Hospital Infection Therapeutics Market: Key Players
目次
Product Code: SR112024A2393

The global hospital infection therapeutics market size reached US$ 12.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.9 Billion by 2032, exhibiting a growth rate (CAGR) of 4.55% during 2024-2032. The escalating incidence of multidrug-resistant infections, a growing emphasis on antimicrobial stewardship, continuous advancements in research and development (R&D), and increased healthcare expenditure and infrastructure development worldwide represent some of the key factors influencing the market growth.

Hospital Infection Therapeutics Market Analysis:

Market Growth and Size: The global hospital infection therapeutics market is experiencing robust growth, driven by an increasing incidence of hospital-acquired infections and the demand for effective treatment solutions. The market size is expanding steadily, fueled by rising healthcare expenditure and infrastructure development worldwide.

Major Market Drivers: Key drivers include the prevalence of multidrug-resistant infections, growing awareness of antimicrobial stewardship programs, continuous advancements in R&D, and a rise in healthcare expenditure globally.

Technological Advancements: Ongoing technological advancements, particularly in genomics, microbiology, and immunology, are contributing to the discovery of novel drug targets and the development of advanced hospital infection therapeutics, such as monoclonal antibodies and combination therapies.

Industry Applications: Hospital infection therapeutics are applied across various indications, including bloodstream infections, urinary tract infections (UTI), surgical site infections, pneumonia, and others, addressing specific challenges associated with each category.

Key Market Trends: The rising focus on antimicrobial stewardship, increasing research collaborations, mergers and acquisitions to expand product portfolios, and the development of alternative therapeutics beyond traditional categories are some of the emerging trends strengthening the market growth.

Geographical Trends: Geographically, North America and Europe lead in demand, driven by robust healthcare infrastructures and stringent regulatory frameworks. While Asia Pacific is witnessing significant growth due to increased healthcare investments and infrastructure development.

Competitive Landscape: The competitive landscape is intense, with pharmaceutical companies engaged in R&D, strategic collaborations, and mergers and acquisitions. The emphasis on aligning products with antimicrobial stewardship principles shapes industry strategies.

Challenges and Opportunities: The emergence of drug-resistant strains is creating challenges for market development, while opportunities lie in addressing specific indications within the hospital infection spectrum and leveraging technological innovations for therapeutic development.

Hospital Infection Therapeutics Market Trends:

Increasing incidence of hospital-acquired infections (HAIs):

One of the primary drivers of the hospital infection therapeutics market is the rising incidence of HAIs. These infections can be bacterial, viral, or fungal in nature and are often associated with invasive medical procedures, surgeries, or the use of medical devices. The prevalence of HAIs is a major concern globally, leading to an increased demand for effective therapeutics to manage and treat these infections. Besides this, the spread of drug-resistant pathogens within healthcare settings has further intensified the need for advanced and targeted treatment options, necessitating the development of innovative and potent therapeutics to combat these infections effectively.

Growing awareness of antimicrobial stewardship programs

Antimicrobial stewardship programs have gained prominence as a key strategy to combat the emergence and spread of antimicrobial resistance. These programs focus on optimizing the use of antimicrobial agents to improve patient outcomes while minimizing the development of resistance. The growing awareness of antimicrobial stewardship has led to an increased emphasis on the development and adoption of novel therapeutics that can address the specific challenges posed by drug-resistant pathogens, creating a positive outlook for market expansion. Moreover, various healthcare organizations and regulatory bodies across the globe are actively promoting antimicrobial stewardship to ensure the judicious use of antibiotics and other antimicrobial agents are providing an impetus to the market growth.

Significant advancements in R&D activities

Ongoing R&D activities in the field of infectious diseases have contributed significantly to the expansion of the hospital infection therapeutics market. In line with this, advancements in genomics, microbiology, and immunology have provided valuable insights into the mechanisms of infection and the identification of novel drug targets. The discovery of new antimicrobial compounds and the development of combination therapies are aiding in market expansion. In addition to this, extensive collaborations between pharmaceutical companies, academic institutions, and research organizations have propelled the discovery and development of innovative therapeutic modalities, including monoclonal antibodies, vaccines, and novel antibiotics, thereby impelling the market growth.

Rising healthcare expenditure and infrastructure development

The global increase in healthcare expenditure and ongoing infrastructure development in the healthcare sector are fueling the growth of the hospital infection therapeutics market. Concurrent with this, numerous governments and private investors are investing in the expansion and modernization of healthcare facilities, including hospitals and clinics. This, in turn, drives the demand for infection therapeutics to equip healthcare providers with effective tools to manage and control the incidence of HAIs, thus bolstering the market growth. Furthermore, the expansion of healthcare infrastructure in emerging economies has opened up new markets for hospital infection therapeutics. As healthcare access improves, there is a surging demand for advanced treatment options to address the healthcare challenges associated with infectious diseases.

Hospital Infection Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug type and indication.

Breakup by Drug Type:

Anti-bacterial Drugs

Anti-fungal Drugs

Anti-viral Drugs

Others

Anti-bacterial drugs accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug type. This includes anti-bacterial, anti-fungal, anti-viral, and other drugs. According to the report, anti-bacterial drugs represented the largest segment.

The rising demand for anti-bacterial hospital infection therapeutics driven by the escalating threat of multidrug-resistant bacteria, necessitating the development of effective antibiotics to combat evolving bacterial strains is fostering market expansion.

In confluence with this, the increasing prevalence of invasive fungal infections, particularly in immunocompromised patients, is propelling the demand for anti-fungal drugs, addressing the unique challenges posed by fungal hospital-acquired infections.

Additionally, the expanding demand for targeted anti-viral hospital infection therapeutics due to the persistent threat of viral outbreaks, such as influenza and emerging viruses is acting as another significant growth-inducing factor.

Diverse infectious agents and evolving resistance patterns spurring the demand for innovative therapeutics beyond conventional categories and leading to the development of alternative drugs to address specific hospital infection challenges are presenting lucrative opportunities for market expansion.

Breakup by Indication:

Blood Stream Infections

Urinary Tract Infections

Surgical Site Infections

Pneumonia

Others

Surgical site infections holds the largest share of the industry

A detailed breakup and analysis of the market based on the indication have also been provided in the report. These include blood stream infections, urinary tract infections, surgical site infections, pneumonia, and others. According to the report, surgical site infections accounted for the largest market share.

The escalating concerns about surgical site infections due to the risk they pose to postoperative recovery are bolstering the need for specialized drugs to prevent and manage infections at surgical sites, thereby propelling the market forward.

The critical nature of blood stream infections, necessitating effective treatments to prevent systemic complications and improve patient outcomes is contributing to the increasing demand and sales of hospital infection therapeutics.

Concurrently, the rising incidences of urinary tract infections (UTIs) are further boosting the demand for therapeutics, with a focus on addressing the specific challenges associated with UTIs, including recurrent infections and antibiotic resistance.

Moreover, the increasing complexity associated with respiratory infections like pneumonia is also fostering the demand for effective hospital infection therapeutics to combat bacterial, viral, and fungal pneumonia, ensuring optimal patient care.

Apart from this, growing cases of skin and soft tissue infections, gastrointestinal infections, and respiratory tract infections driving the demand for specialized hospital infection therapeutics are influencing market expansion.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Europe leads the market, accounting for the largest hospital infection therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share.

The rising awareness of infectious diseases, well-established healthcare systems, and a proactive approach to antimicrobial stewardship in Europe leading to a continuous need for advanced therapeutics are contributing to the market expansion.

Moreover, North America's robust healthcare infrastructure, stringent regulatory frameworks, and a high prevalence of healthcare-associated infections necessitating effective treatment solutions are positively impacting the market growth.

Furthermore, extensive healthcare investments, a growing burden of infectious diseases, and a surge in hospital infrastructure development in the Asia Pacific are creating remunerative opportunities for the expansion of the hospital infection therapeutics market.

Besides this, Latin America's evolving healthcare policies and supportive efforts aimed at enhancing healthcare accessibility while expanding healthcare infrastructure and a rising focus on healthcare quality in the Middle East and Africa emphasizing the need for advanced hospital infection therapeutics are propelling the market growth.

Leading Key Players in the Hospital Infection Therapeutics Industry:

The global hospital infection therapeutics market is characterized by intense competition among pharmaceutical companies striving to address the increasing prevalence of hospital-acquired infections. Key players in the market are engaged in extensive R&D activities to introduce innovative therapeutics, ranging from antibiotics to antiviral drugs, tailored to combat multidrug-resistant pathogens. Strategic collaborations and partnerships between industry players, academic institutions, and research organizations are commonplace, fostering the exchange of knowledge and expertise. The emphasis on antimicrobial stewardship programs further shapes the competitive landscape, with companies working to align their products with principles promoting the judicious use of antimicrobial agents. Regulatory compliance, market penetration strategies, and a focus on addressing specific indications within the hospital infection spectrum are pivotal factors influencing the competitive dynamics of this dynamic and evolving market.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Allergan Plc (AbbVie Inc.)

AstraZeneca Plc

Bayer Aktiengesellschaft

Bristol-Myers Squibb Company

F. Hoffmann-La Roche AG (Roche Holding AG)

Gilead Sciences Inc.

GlaxoSmithKline plc

Johnson & Johnson

Merck & Co. Inc

Pfizer Inc.

Sanofi S.A.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

In December 2023, F. Hoffmann-La Roche AG (Roche Holding AG) entered into a definitive merger agreement to acquire Carmot Therapeutics, Inc. ("Carmot"), a privately owned US company based in Berkeley, California.

In October 2023, Gilead announced its collaboration with Assembly Biosciences to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio's established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D virus (HDV).

In March 2023, GSK plc and SCYNEXIS, Inc. announced that they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA-approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC (RVVC).

Key Questions Answered in This Report:

  • How has the global hospital infection therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global hospital infection therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global hospital infection therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive hospital infection therapeutics market?
  • What is the breakup of the market based on the drug type?
  • Which is the most attractive drug type in the hospital infection therapeutics market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the hospital infection therapeutics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global hospital infection therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Infection Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Anti-bacterial Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anti-fungal Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Anti-viral Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Blood Stream Infections
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Urinary Tract Infections
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Surgical Site Infections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pneumonia
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Allergan Plc (AbbVie Inc.)
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bayer Aktiengesellschaft
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bristol-Myers Squibb Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 SWOT Analysis
    • 13.3.6 Gilead Sciences Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 GlaxoSmithKline Plc
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Johnson & Johnson
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sanofi S.A.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis